Skip to main content

Document Security Systems(DSS-A)
NYSE Arca

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir

Globe Newswire - Tue Jun 28, 2022

HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and Discovery Group Sciences (GRDG), announced today that it signed a license agreement with ProPhase Labs (NASDAQ: PRPH) for Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.